Aytu BioPharma Q3 2024 GAAP EPS $(0.52) Beats $(0.64) Estimate, Sales $17.993M Beat $17.346M Estimate
Aytu BioPharma Q3 2024 GAAP EPS $(0.52) Beats $(0.64) Estimate, Sales $17.993M Beat $17.346M Estimate
Aytu BioPharma 2024年第三季度GAAP每股收益美元（0.52美元）超过预期（0.64美元），销售额1799.3万美元超过预期的173.46亿美元
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.64) by 18.75 percent. This is a 73.06 percent increase over losses of $(1.93) per share from the same period last year. The company reported quarterly sales of $17.993 million which beat the analyst consensus estimate of $17.346 million by 3.73 percent. This is a 20.85 percent decrease over sales of $22.733 million the same period last year.
艾图生物制药（纳斯达克股票代码：AYTU）公布的季度亏损为每股0.52美元，比分析师普遍预期的0.64美元（0.64美元）高出18.75％。与去年同期每股亏损1.93美元（1.93）相比，增长了73.06％。该公司公布的季度销售额为1799.3万美元，比分析师普遍预期的1734.6万美元高出3.73％。这比去年同期的2,273.3万美元的销售额下降了20.85％。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。